Vivos Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Vivos Therapeutics şirketinin toplam hissedar öz sermayesi $7.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $15.3M ve $7.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$6.31m
Eşitlik	US$7.67m
Toplam yükümlülükler	US$7.68m
Toplam varlıklar	US$15.35m

Son finansal sağlık güncellemeleri

Recent updates

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Nov 12

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Sep 10

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Apr 25

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Feb 02

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Apr 18

Vivos Therapeutics again delays Q2 2022 results

Aug 23

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Jun 29

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

May 21

Vivos Therapeutics: First Take After The Broad Market Sell-Off

Mar 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VVOS 'nin kısa vadeli varlıkları ( $7.4M ) kısa vadeli yükümlülüklerini ( $5.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: VVOS şirketinin kısa vadeli varlıkları ( $7.4M ) uzun vadeli yükümlülüklerini ( $2.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VVOS borçsuzdur.

Borcun Azaltılması: VVOS şirketinin 5 yıl önce borç/öz sermaye oranı 1752.4% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: VVOS şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: VVOS un, serbest nakit akışı her yıl % 16.2 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Vivos Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Vivos Therapeutics Provides Non-Compliance Update

Vivos Therapeutics Provides Nasdaq Compliance Update

Vivos Therapeutics Receives a Written Notice from the Nasdaq

Vivos Therapeutics Receives Non-Compliance Letterer from Nasdaq

Vivos Therapeutics, Inc. announced delayed 10-Q filing

Vivos Therapeutics Receives Staff Deficiency Notice from The Nasdaq Stock Market Due to Failure to File its Form 10-Q

Recent updates

Consensus EPS estimates upgraded to US$2.02 loss, revenue downgraded

Price target decreased by 14% to US$6.30

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Vivos Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Vivos Therapeutics, Inc., Annual General Meeting, Nov 26, 2024

New major risk - Share price stability

Vivos Therapeutics, Inc. Receives FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Consensus estimates of losses per share improve by 31%

New major risk - Financial position

Vivos Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Vivos Therapeutics Announces Positive Results from 7-Month Multi-Site Pilot of Its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics, Inc. announced that it has received $7.5 million in funding

Vivos Therapeutics Provides Non-Compliance Update

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Vivos Therapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Vivos Therapeutics, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Vivos Therapeutics, Inc. Receives FDA Clearance to Vivos Care Oral Appliances to Treat Severe OSA in Adults

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Vivos Therapeutics, Inc. Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA

Vivos Therapeutics, Inc. Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.7% to US$45.00

High number of new and inexperienced directors

Vivos Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Vivos Therapeutics, Inc. announced that it has received $4.000003 million in funding

Vivos Therapeutics, Inc. announced that it expects to receive $4.000003 million in funding

Vivos Therapeutics Provides Nasdaq Compliance Update

Vivos Therapeutics Receives a Written Notice from the Nasdaq

Vivos Therapeutics, Inc., Annual General Meeting, Sep 22, 2023

Vivos Therapeutics Receives Non-Compliance Letterer from Nasdaq

Vivos Therapeutics, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Vivos Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Vivos Therapeutics, Inc. to Report Q1, 2023 Results on Jun 08, 2023

Vivos Therapeutics Receives Staff Deficiency Notice from The Nasdaq Stock Market Due to Failure to File its Form 10-Q

Vivos Therapeutics, Inc. announced delayed 10-Q filing

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Consensus EPS estimates upgraded to US$0.40 loss

Price target decreased by 17% to US$1.88

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.26 loss per share (vs US$0.26 loss in 3Q 2021)

Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements

Vivos Therapeutics, Inc. Receives FDA 510(k) Clearance of its DNA Oral Appliance for Treatment of Obstructive Sleep Apnea

Vivos Therapeutics, Inc. to Report Q3, 2022 Results on Dec 20, 2022

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

Vivos Therapeutics Receives a Staff Deficiency Notice from The Nasdaq Stock Market

Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Vivos Therapeutics again delays Q2 2022 results

Vivos Therapeutics, Inc. announced delayed 10-Q filing

Vivos Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Vivos Therapeutics, Inc. Receives Multiple Class I Clearances by Therapeutic Goods Administration (TGA) of Australia

Vivos Therapeutics, Inc., Annual General Meeting, Aug 25, 2022

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Vivos Therapeutics, Inc. Presents Positive Results from a Retrospective Study with Vivos Patients

Consensus revenue estimates fall by 25%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$9.00

High number of new and inexperienced directors

No longer forecast to breakeven